No. of all participants (%): 181 (100%) | No. of JCPyV positive subjects (%): 11 (6.1%) | No. of JCPyV negative subjects (%):170 (93.9%) | Adjusted OR (95% CI) | P-Value | |
---|---|---|---|---|---|
Age groups (years) | |||||
27–39 | 7 (3.9) | 2 (18.2) | 5 (2.9) | 1.0 | |
40–49 | 15 (8.3) | 1 (9.1) | 14 (8.2) | 5.600 (0.412–76.049) | 0.196 |
50–59 | 46 (25.4) | 0 (0.0) | 46 (27.1) | 0.000 | 0.997 |
60–69 | 45 (24.9) | 2 (18.2) | 43 (25.3) | 8.600 (0.984–75.151) | 0.052 |
70–79 | 39 (21.5) | 6 (54.5) | 33 (19.4) | 2.200 (0.344–14.079) | 0.405 |
≥ 80 | 29 (16.0) | 0 (0.0) | 29 (17.1) | 0.000 | 0.998 |
Gender | |||||
Male | 138 (76.2) | 9 (81.8) | 129 (75.9) | 1.0 | |
Female | 43 (23.8) | 2 (18.2) | 41 (24.1) | 1.430 (0.297–6.888) | 0.655 |
Place of residence (city) | |||||
Bushehr | 63 (34.8) | 2 (18.2) | 61 (35.9) | 1.0 | |
Tangestan | 27 (14.9) | 4 (36.4) | 23 (13.5) | 0.189 (0.032–1.100) | 0.064 |
Dashtestan | 38 (21.0) | 1 (9.1) | 37 (21.8) | 1.213 (0.106–13.848) | 0.876 |
Dashti | 25 (13.8) | 1 (9.1) | 24 (14.1) | 0.787 (0.068–9.087) | 0.848 |
Dayer | 11 (6.1) | 1 (9.1) | 10 (5.9) | 0.328 (0.027–3.962) | 0.380 |
Deylam | 3 (1.7) | 1 (9.1) | 2 (1.2) | 0.066 (0.004–1.06) | 0.055 |
Kangan | 5 (2.8) | 0 (0.0) | 5 (2.9) | 0.000 | 0.999 |
Genaveh | 8 (4.4) | 1 (9.1) | 7 (4.1) | 0.230 (0.018–2.866) | 0.253 |
Jam | 1 (0.6) | 0 (0.0) | 1 (0.6) | 0.000 | 1.000 |
Stage of tumor | |||||
Ta–T1 | 166 (91.7) | 10 (90.9) | 156 (91.8) | 1.0 | |
T2–T3 | 15 (8.3) | 1 (9.1) | 14 (8.2) | 0.897 (0.107–7.530) | 0.921 |
Grade of tumor | |||||
Urothelial papilloma | 4 (2.2) | 0 (0.0) | 4 (2.4) | 1.0 | |
Papillary urothelial neoplasms of low malignant | 62 (34.3) | 3 (27.3) | 59 (34.7) | 0.000 | 0.999 |
Low-grade papillary urothelial carcinoma | 68 (37.6) | 4 (36.4) | 64 (37.6) | 0.000 | 0.999 |
High-grade papillary urothelial carcinoma | 47 (26.0) | 4 (36.4) | 43 (25.3) | 0.000 | 0.999 |